MYC dysregulation confers a poor prognosis to diffuse large B-cell lymphoma (DLBCL), and effective therapeutic strategies are lacking in relapsed/refractory DLBCL, Burkitt lymphoma and intermediate forms.^[@bib1],\ [@bib2]^ As a master transcriptional regulator, MYC recruits transcription complexes containing RNA polymerase II (Pol II) to facilitate effective transcriptional elongation of MYC gene targets.^[@bib3]^ Pol II is fully activated by phosphorylation of a critical serine residue at position 2 within heptapeptide repeats in the carboxy-terminal domain (CTD), a function performed by the positive transcription elongation factor b (P-TEFb; comprising CDK9 and cyclin T1).^[@bib4]^ It has been shown that MYC binds and recruits P-TEFb to its targets as a means to activate Pol II.^[@bib3],\ [@bib5],\ [@bib6]^ More recently, CDK9-mediated transcriptional elongation was reported as essential for tumor maintenance in a genetically defined MYC-driven model of hepatocellular carcinoma.^[@bib7]^ Thus, CDK9 dependence may represent a druggable vulnerability in lymphomas with dysregulated MYC expression.

Dinaciclib (Merck, Boston, MA, USA) is a novel CDK inhibitor that has reached phase 1b/2 of clinical trials for a range of solid-organ malignancies, as well as for myeloma and chronic lymphocytic leukemia.^[@bib8]^ We hypothesized that CDK9 inhibition by dinaciclib would represent a rational pharmacologic approach to target the transcription of critical MYC-regulated oncogenic effector proteins. Here we describe durable *in vivo* responses to dinaciclib in aggressive MYC-driven lymphoma, mediated by downregulation of Pol II-mediated Mcl-1 transcription.

Dinaciclib has 50% kinase inhibitory concentrations of 1, 1, 3 and 4 n[M]{.smallcaps} for CDK2, CDK5, CDK1 and CDK9, respectively.^[@bib8]^ Dinaciclib potently killed Eμ-*Myc* and human *IG-cMYC-*translocated cell lines independent of p53 function, but not untransformed murine fibroblast cells, at low nanomolar concentrations approximating those observed for kinase inhibition ([Figures 1a and b](#fig1){ref-type="fig"}, [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}).

As Bcl-2 and Mcl-1 have been implicated as important apoptotic regulators in Eμ-*Myc* lymphomas,^[@bib9],\ [@bib10]^ we assessed the effects of dinaciclib on these proteins. We hypothesized that CDK9 inhibition with dinaciclib would target Mcl-1 transcription, as has been observed with other CDK inhibitors in myeloma and mantle cell lymphoma.^[@bib11],\ [@bib12]^ Eμ-*Myc* and human *IG-cMYC-*translocated cell lines were treated with dinaciclib or dimethylsulfoxide control and interrogated using the quantitative PCR analysis for the effect on Mcl-1 and Bcl-2 mRNA. Dinaciclib treatment was associated with a significant reduction in Mcl-1 mRNA, with no significant effect on Bcl-2 transcript levels ([Figure 1c](#fig1){ref-type="fig"}, [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). Chromatin immunoprecipitation-PCR was used to show the binding of phosphorylated Pol II, subunit B1 carboxy-terminal domain (CTD) serine 2 (pRpb1 Ser2) as a marker of CDK9 activity at the *Mcl-1* locus in a representative Eμ-*Myc* lymphoma cell line ([Figure 1d](#fig1){ref-type="fig"}). These findings support the hypothesis that dinaciclib transcriptionally downregulates Mcl-1.

We next examined Mcl-1 expression in Eμ-*Myc* and human *IG-cMYC-*translocated lymphoma cell lysates following the treatment with dinaciclib or vehicle. On-target CDK9 inhibition by dinaciclib was confirmed through inhibition of pRpb1 Ser2 at concentrations corresponding to apoptosis induction in Eμ-*Myc* cells ([Figure 1e](#fig1){ref-type="fig"}). Dinaciclib treatment also rapidly suppressed Mcl-1 protein expression, with no discernible reduction in Bcl-2 or Bcl-x~L~ protein observed in murine ([Figure 1e](#fig1){ref-type="fig"}) or human ([Figure 1f](#fig1){ref-type="fig"}) cells. To determine the functional importance of Mcl-1 in regulating dinaciclib-mediated apoptosis, a representative Eμ-*Myc* lymphoma was stably transduced to express Mcl-1 off a retroviral promoter. As shown in [Figure 1g](#fig1){ref-type="fig"}, exogenously expressed Mcl-1 significantly protected Eμ-*Myc* cells from dinaciclib-induced apoptosis.

The *in vivo* efficacy of dinaciclib was then assessed by transplanting the same Eμ-*Myc* lymphomas into cohorts of syngeneic C57Bl/6 recipients. Compared with the vehicle control, dinaciclib treatment was well tolerated and associated with a highly significant survival advantage of tumor-bearing mice, including those bearing a p53-null lymphoma and a lymphoma with a spontaneous p53 mutation encoding a dominant-negative p53 protein ([Figures 2a--c](#fig2){ref-type="fig"}, [Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). In contrast, dinaciclib-mediated therapeutic efficacy was severely attenuated in isogeneic p53-competent Eμ-*Myc* lymphoma overexpressing Mcl-1 ([Figure 2d](#fig2){ref-type="fig"}). In separate experiments, mice bearing transplanted Eμ-*Myc* cells were left untreated for 12 days to establish bulky nodal disease, at which time they received a single dose of dinaciclib or vehicle 1 or 4 h before being killed and before the lymph nodes were harvested. Consistent with the *in vitro* data, lymph node protein lysates showed reductions of pRpb1 and total Mcl-1 protein ([Figure 2e](#fig2){ref-type="fig"}), concomitant with the induction of apoptosis ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}). Finally, dinaciclib treatment of immunocompromised mice xenografted with the human *IG-cMYC-*translocated lymphoma was associated with reduced disease progression and significantly prolonged overall survival ([Figures 2f and g](#fig2){ref-type="fig"}).

In conclusion, our findings indicate that CDK9 inhibition by dinaciclib is highly effective in aggressive MYC-driven lymphomas, including 'poor-risk\' p53-deficient clones, via selective inhibition of critical MYC targets including Mcl-1 (which is currently undruggable with existing BH3 mimetics).^[@bib13],\ [@bib14]^ Our data suggest a linear and druggable dependency between MYC and Mcl-1 that is contingent on CDK9 signaling. These findings are of particular interest in the context of a recent publication by Kelly *et al.*,^[@bib15]^ further highlighting the dependency of MYC-driven B-cell lymphoma to Mcl-1. Rapid clinical translation of CDK9 inhibitors to MYC-dysregulated lymphoid malignancy should now be considered.
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![Dinaciclib potently induces apoptosis of murine Eμ-*Myc* and human *IG-cMYC-*translocated lymphomas with rapid and selective suppression of Mcl-1 transcription and protein levels. (**a**) Wild-type p53 (^\#^4242) and p53-null (^\#^3391) Eμ-*Myc* lymphomas were cultured *in vitro* with dimethylsulfoxide (DMSO) vehicle control or dinaciclib for 24 h and then analyzed using flow cytometric analysis for annexin-V/propidium iodide (PI) positivity. (**b**) Human *IG-cMYC-*translocated BL-41 and Ramos cell lines were cultured *in vitro* with DMSO or dinaciclib for 48 h before the analysis of annexin-V/PI positivity using flow cytometry. (**c**) Mcl-1 and Bcl-2 mRNA expression in lymphoma ^\#^4242 following 3-h *in vitro* treatment with DMSO or 20 n[M]{.smallcaps} dinaciclib. Transcript levels are represented as fold change compared with DMSO. NS, not significant; \**P*\<0.0001. (**d**) Chromatin immunoprecipitation-PCR of Eμ-*Myc* lymphoma ^\#^4242 cells showing binding of phospho-RNA Pol II CTD serine 2 (pRpb1 Ser2) at the *Mcl-1* locus. Error bars denote the s.e.m. from three independent primer sets across the *Mcl-1* locus. (**e**) Eμ-*Myc* lymphoma ^\#^4242 was cultured *in vitro* for 3-h untreated or in the presence of DMSO or 20 n[M]{.smallcaps} dinaciclib before the preparation of lysates and immunoblotting for phospho-RNA Pol II CTD (pRpb1^Ser2^, pRpb1^Ser5^ and pRpb1^Ser2/5^), total Mcl-1, Bcl-2, Bcl-x~L~, c-Myc and HSP90 loading control. (**f**) Human *IG-cMYC-*translocated BL-41 and Ramos cell lines were cultured *in vitro* for 3 h in the presence of DMSO or 20 nM dinaciclib before the preparation of lysates and immunoblotting for total Mcl-1, Bcl-2, Bcl-x~L~, c-Myc, Tubulin and HSP90 loading controls. (**g**) Eμ-*Myc* lymphoma ^\#^4242 was transduced with murine stem cell virus expressing empty vector control or *Mcl-1* and then cultured *in vitro* with dinaciclib for 24 h before flow cytometric analysis for annexin-V/PI positivity. \*\**P*\<0.01 comparing treatments at 16 n[m]{.smallcaps} concentration. All graphs represent the mean±s.e.m (error bars) for three or more independent experiments.](leu201510f1){#fig1}

![Dinaciclib therapy prolongs the survival of mice bearing Eμ-*Myc* and human *IG-cMYC-*translocated lymphomas. (**a--d**) Kaplan--Meier survival curves representing cohorts of C57Bl/6 mice transplanted with representative Eμ-*Myc* lymphomas 3 days before the therapy commencement with 20% hydroxypropyl-beta-cyclodextran (HPBCD) vehicle or 30 mg/kg dinaciclib by intraperitoneal injection twice weekly. Gray shading denotes the period of therapy. dn, dominant negative; *P\<*0.0001 for each experiment. The median survival for vehicle- and dinaciclib-treated mice were 12 days and not reached (^\#^4242), 16 and 48 days (^\#^3391), 18 and 66 days (^\#^106) and 13 and 18 days (^\#^4242tMcl-1), respectively. (**e**) Lymph nodes were harvested from cohorts of C57Bl/6 mice 1 or 4 h following a single dose of dinaciclib or 20% HPBCD, 12 days following transplantation with Eμ-*Myc* lymphoma ^\#^4242. Protein lysates were then prepared and separated by sodium dodecyl sulfate--polyacrylamide gel electrophoresis before immunoblotting for the indicated targets. Each lane represents protein lysate from the lymph nodes of an individual mouse. (**f**) Bioluminescence imaging of NOD-scid IL2Rγ^null^ mice transplanted with human *IG-cMYC-*translocated BL-41.*luc2* lymphoma 3 days before the commencement of the therapy with 20% HPBCD vehicle or 30 mg/kg dinaciclib by intraperitoneal injection twice weekly. Mice were imaged at 7 and 14 days post transplantation. (**g**) Overall survival of the mice from the experiment is described in **f**. Gray shading denotes the period of therapy. The median survival for vehicle and dinaciclib-treated mice were 19 and 26 days, respectively (*P*\<0.001).](leu201510f2){#fig2}
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